



## Entasis Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

December 5, 2018

WALTHAM, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- [Entasis Therapeutics](#) (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced that Manos Perros, President and Chief Executive Officer, will present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York, NY.

Event: BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

Date: December 12, 2018 at 1:40 PM ET

Location: Mandarin Oriental Hotel, New York, NY

A live webcast of the presentation can be accessed under "Investors & Media" in the "News & Events" section of the Company's website at [www.entasistx.com](http://www.entasistx.com).

### About Entasis

Entasis Therapeutics is developing a portfolio of innovative product candidates to treat serious Gram-negative multi-drug resistant bacterial infections. Entasis' anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting *Acinetobacter baumannii* infections), zoliflodacin (targeting *Neisseria gonorrhoeae*), ETX0282CPDP (targeting *Enterobacteriaceae* infections), and non- $\beta$ -lactam PBP inhibitors or NBPs (targeting Gram-negative infections). [www.entasistx.com](http://www.entasistx.com)

### Company Contact

Kyle Dow

Entasis Therapeutics

(781) 810-0114

[kyle.dow@entasistx.com](mailto:kyle.dow@entasistx.com)

### Investor Contact

Chris Brinzey

Westwicke Partners

(339) 970-2843

[Chris.brinzey@westwicke.com](mailto:Chris.brinzey@westwicke.com)

### Media Contact

Kari Watson or Stefanie Tuck

MacDougall Biomedical Communications

(781) 235-3060

[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com) or [stuck@macbiocom.com](mailto:stuck@macbiocom.com)

Source: Entasis Therapeutics Holdings Inc.